Selahattin ÖZTAŞ, Müge ÖZDEMİR, Güliz ATAÇ, Melahat KURUTEPE, Özlen TÜMER, Yelda TEZEL, Eylem ACARTÜRK, Ali Vefa ÖZTÜRK, Gül ERDAL

The role of tumor SUVmax/lymph node SUVmax ratio viewed on PET-CT in the detection of mediastinal metastasis in patients with lung cancer

Amaç: Bu çalışmada, küçük hücreli dışı akciğer kanseri (KHDAK) hastalarında mediastinal lenf nodu evrelemesinde pozitron emisyon tomografi-bilgisayarlı tomografinin (PET-BT) duyarlığını saptamada lenf nodu standardize alım değeri (SUDmax)/kitle SUDmax oranı araştırıldı. Çalışma planı: Çalışmamıza Ocak 2007 - Ekim 2010 tarihleri arasında Süreyyapaşa Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi 9. Göğüs Hastalıkları kliniğinde patolojik olarak kanıtlanmış 31 KHDAK hastası (3 kadın, 28 erkek; ort. yaş 61.0±9.2 yıl; dağılım 35-79 yıl) alındı. Bu hastalar evreleme amacıyla PET-BT çekilmiş ve mediastinoskopi yapılmış hastalar idi. Mediastinoskopi ile patolojik tanısı gösterilen lenfadenomegalilerin (lenf nodu) PET-BT SUDmax değerleri primer kitlenin SUDmax değeri ile karşılaştırılarak, kitle SUDmax/lenf nodu SUDmax oranları saptandı. Bu oranlar 1.5 ve 2.5 kesme değerleri ile üç gruba ayrılarak, metastazı saptamadaki doğrulukları incelendi. Bulgular: Lenfadenomegali patolojisi sonucu pozitif olan olgular ile negatif olan olguların kitle SUDmax düzeyleri arasında istatistiksel olarak anlamlı bir farklılık bulunmadı (p>0.05). Lenfadenomegali patolojisi sonucu pozitif olan olguların lenf nodu SUDmax düzeyleri, patoloji sonucu negatif olan olgulardan istatistiksel olarak ileri düzeyde anlamlı yüksek idi (p

Akciğer kanserli hastalarda PET-BT'de görüntülenen tümör SUDmax/lenf nodu SUDmax oranlarının mediastinal metastaz tespitindeki yeri

Background: In this study, we aimed to investigate the lymph node standardized uptake value (SUVmax)/mass SUVmax ratio for the determination of sensitivity of positron emission tomography-computed tomography (PET-CT) in mediastinal lymph node staging in patients with non-small cell lung cancer (NSCLC). Methods: A total of 31 patients (3 female, 28 males; mean age 61.0±9.2 years; range 35 to 79 years) with pathologically confirmed diagnosis of NSCLC in Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, 9th Chest Diseases Clinic between January 2007 and October 2010 were included. These patients underwent PET-CT and mediastinoscopy for staging. The mass SUVmax/lymphadenomegaly (lymph node) SUVmax ratios were determined by comparing the primary mass SUVmax with the PET-CT SUVmax value of lymph node with mediastinoscopy-confirmed pathological diagnosis. The reliability of these ratios in detecting metastasis was assessed by dividing the ratios into three groups using the 1.5 and 2.5 cut-off values. Results: No statistically significant difference was found between patients with positive lymph node results and those with negative results with regards to the mass SUVmax levels (p>0.05). The lymph node SUVmax levels of patients with positive lymph node pathology results were found to be statistically significantly higher than in patients with negative pathology results (p

PDF

___

1. Özbay B, Uzun K, Yalçınkaya İ. Son üç yıl içinde ilimizde saptadığımız akciğer tümörü olgularının değerlendirilmesi. Tüberküloz ve Toraks Dergisi 1999;47:77-82.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
3. Shields TW. Lung cancer: surgical treatment of non-small cell lung cancer. In: Shields TW, Ponn RB, Locicero J, editors. General thoracic surgery. Chapter 99. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2000. p. 1311-43.
4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
5. Johnston MR. Invasive staging of the mediastinum. World J Surg 1993;17:700-4.
6. Shields TW. Lung cancer: diagnosis and staging of lung cancer. In: Shields TW, Ponn RB, Locicero J, editors. General thoracic surgery. Chapter 98, 58. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2000. p. 1297-1311.
7. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37:1428-36.
8. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging nonsmall cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705-13.
9. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.
10. Saunders CA, Dussek JE, O’Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7.
11. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1-92.
12. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642-8.
13. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
14. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-21.
15. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.
16. Eroğlu O, Tanju S, Toker A, Ziyade S, Dilege Ş, Kalaycı G.Küçük hücreli dışı akciğer kanserinde mediastinal lenf nodu evrelemesinde pozitron emisyon tomografisinin yeri. Turk Gogus Kalp Dama 2007;15:133-8.
17. Cerfolio RJ, Ojha B, Bryant AS, Bass CS, Bartalucci AA, Mountz JM. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 2003;76:861-6.
18. Cansever L, Hacıibrahimoğlu G, Kocatürk C, Sönmezoğlu K, Bedirhan AM. Küçük hücreli dışı akciğer kanseri cerrahisinde 18F-FDG-PET’in evrelemedeki yeri. Toraks Dergisi 2006;7:145-50.
19. Gonzalez-Stawinski GV, Lemaire A, Merchant F, O'Halloran E, Coleman RE, Harpole DH, D’Amico TA. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1900-5.
20. Kernstine KH, Stanford W, Mullan BF, Rossi NP, Thompson BH, Bushnell DL, et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 1999;68:1022-8.
21. Kim BT, Kim Y, Lee KS, Yoon SB, Cheon EM, Kwon OJ, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 1998;170:935-9.
22. Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235-42.
23. Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schäfers HJ. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 2003;75:231-5.
24. Yılmazbayhan D. Akciğer tümörlerinde patoloji. In: Yüksel M, Kalaycı NG, editörler. Göğüs cerrahisi. İstanbul: Bilmedya Grup; 2001. s. 221-31.
25. Hiroaki T, Kazuya K, Taeko N, Mituteru Y, Kouichiro K, Takanori M, et al. Evaluation of FDG-PET/CT for lung cancer and lymph nodes metastasis. Journal of Thoracic Oncology 2007;2:587-8.
26. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016-20.
27. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 2006;82:417-22.
28. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-24.
29. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose- positron emission tomography scan in non-smallcell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6.